These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 25819366)

  • 1. Higher infection rate after 7- compared with 5-day cycle of azacitidine in patients with higher-risk myelodysplastic syndrome.
    Ofran Y; Filanovsky K; Gafter-Gvili A; Vidal L; Aviv A; Gatt ME; Silbershatz I; Herishanu Y; Arad A; Tadmor T; Dally N; Nemets A; Rouvio O; Ronson A; Herzog-Tzarfati K; Akria L; Braester A; Hellmann I; Yeganeh S; Nagler A; Leiba R; Mittelman M; Merkel D
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):e95-9. PubMed ID: 25819366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: a retrospective multicenter study.
    Merkel D; Filanovsky K; Gafter-Gvili A; Vidal L; Aviv A; Gatt ME; Silbershatz I; Herishanu Y; Arad A; Tadmor T; Dally N; Nemets A; Rouvio O; Ronson A; Herzog-Tzarfati K; Akria L; Braester A; Hellmann I; Yeganeh S; Nagler A; Leiba R; Mittelman M; Ofran Y
    Am J Hematol; 2013 Feb; 88(2):130-4. PubMed ID: 23345248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infection Rate and Risk Factors in Patients Treated With Azacitidine.
    Orero M; Villegas C; Ortiz S; Javier KP; Costa S; Pérez PL; Roig M; Linares M
    Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):e141-2. PubMed ID: 26257105
    [No Abstract]   [Full Text] [Related]  

  • 4. Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia.
    García-Delgado R; de Miguel D; Bailén A; González JR; Bargay J; Falantes JF; Andreu R; Ramos F; Tormo M; Brunet S; Figueredo A; Casaño J; Medina A; Badiella L; Jurado AF; Sanz G
    Leuk Res; 2014 Jul; 38(7):744-50. PubMed ID: 24795069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence, etiology and timing of infections following azacitidine therapy for myelodysplastic syndromes.
    Trubiano JA; Dickinson M; Thursky KA; Spelman T; Seymour JF; Slavin MA; Worth LJ
    Leuk Lymphoma; 2017 Oct; 58(10):2379-2386. PubMed ID: 28278704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive Model for Infection Risk in Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia Patients Treated With Azacitidine; Azacitidine Infection Risk Model: The Polish Adult Leukemia Group Study.
    Mądry K; Lis K; Biecek P; Młynarczyk M; Rytel J; Górka M; Kacprzyk P; Dutka M; Rodzaj M; Bołkun Ł; Krochmalczyk D; Łątka E; Drozd-Sokołowska J; Waszczuk-Gajda A; Knopińska-Posłuszny W; Kopińska A; Subocz E; Masternak A; Guzicka-Kazimierczak R; Gil L; Machowicz R; Biliński J; Giebel S; Czerw T; Dwilewicz-Trojaczek J
    Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):264-274.e4. PubMed ID: 30898482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of a 5-day regimen of azacitidine for patients with high-risk myelodysplastic syndromes.
    Fujimaki K; Miyashita K; Kawasaki R; Tomita N
    Eur J Haematol; 2016 Sep; 97(3):228-31. PubMed ID: 26613362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clonal selection in therapy-related myelodysplastic syndromes and acute myeloid leukemia under azacitidine treatment.
    Calleja A; Yun S; Moreilhon C; Karsenti JM; Gastaud L; Mannone L; Komrokji R; Al Ali N; Dadone-Montaudie B; Robert G; Auberger P; Raynaud S; Sallman DA; Cluzeau T
    Eur J Haematol; 2020 May; 104(5):488-498. PubMed ID: 31990086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study.
    Prebet T; Sun Z; Ketterling RP; Zeidan A; Greenberg P; Herman J; Juckett M; Smith MR; Malick L; Paietta E; Czader M; Figueroa M; Gabrilove J; Erba HP; Tallman MS; Litzow M; Gore SD;
    Br J Haematol; 2016 Feb; 172(3):384-91. PubMed ID: 26577691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10-day decitabine regimen.
    Ali AM; Weisel D; Gao F; Uy GL; Cashen AF; Jacoby MA; Wartman LD; Ghobadi A; Pusic I; Romee R; Fehniger TA; Stockerl-Goldstein KE; Vij R; Oh ST; Abboud CN; Schroeder MA; Westervelt P; DiPersio JF; Welch JS
    Cancer Med; 2017 Dec; 6(12):2814-2821. PubMed ID: 29058375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905.
    Prebet T; Sun Z; Figueroa ME; Ketterling R; Melnick A; Greenberg PL; Herman J; Juckett M; Smith MR; Malick L; Paietta E; Czader M; Litzow M; Gabrilove J; Erba HP; Gore SD; Tallman MS
    J Clin Oncol; 2014 Apr; 32(12):1242-8. PubMed ID: 24663049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A limited number of 5-azacitidine cycles can be effective treatment in MDS.
    Müller-Thomas C; Schuster T; Peschel C; Götze KS
    Ann Hematol; 2009 Mar; 88(3):213-9. PubMed ID: 18696067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure.
    Thepot S; Boehrer S; Seegers V; Prebet T; Beyne-Rauzy O; Wattel E; Delaunay J; Raffoux E; Hunault M; Jourdan E; Chermat F; Sebert M; Kroemer G; Fenaux P; Adès L;
    Leuk Res; 2014 Dec; 38(12):1430-4. PubMed ID: 25449687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of treatment with azacitidine in patients aged ≥ 75 years included in the Spanish Registry of Myelodysplastic Syndromes.
    Xicoy B; Jiménez MJ; García O; Bargay J; Martínez-Robles V; Brunet S; Arilla MJ; Pérez de Oteyza J; Andreu R; Casaño FJ; Cervero CJ; Bailén A; Díez M; González B; Vicente AI; Pedro C; Bernal T; Luño E; Cedena MT; Palomera L; Simiele A; Calvo JM; Marco V; Gómez E; Gómez M; Gallardo D; Muñoz J; de Paz R; Grau J; Ribera JM; Benlloch LE; Sanz G
    Leuk Lymphoma; 2014 Jun; 55(6):1300-3. PubMed ID: 23952246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes.
    Lyons RM; Cosgriff TM; Modi SS; Gersh RH; Hainsworth JD; Cohn AL; McIntyre HJ; Fernando IJ; Backstrom JT; Beach CL
    J Clin Oncol; 2009 Apr; 27(11):1850-6. PubMed ID: 19255328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infections in patients with acute myeloid leukemia treated with low-intensity therapeutic regimens: Risk factors and efficacy of antibiotic prophylaxis.
    Bainschab A; Quehenberger F; Greinix HT; Krause R; Wölfler A; Sill H; Zebisch A
    Leuk Res; 2016 Mar; 42():47-51. PubMed ID: 26866663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients.
    Wijermans P; Lübbert M; Verhoef G; Bosly A; Ravoet C; Andre M; Ferrant A
    J Clin Oncol; 2000 Mar; 18(5):956-62. PubMed ID: 10694544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of azacitidine in myelodysplastic syndromes.
    Vigil CE; Martin-Santos T; Garcia-Manero G
    Drug Des Devel Ther; 2010 Sep; 4():221-9. PubMed ID: 20957213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimated glomerular filtration rate independently predicts outcome of azacitidine therapy in higher-risk Myelodysplastic syndromes. Results from 536 patients of the Hellenic National Registry of Myelodysplastic and Hypoplastic syndromes.
    Papadopoulos V; Diamantopoulos PT; Papageorgiou SG; Papoutselis M; Vrachiolias G; Pappa V; Galanopoulos AG; Vassilakopoulos TP; Hatzimichael E; Zikos P; Papadaki HA; Bouchla A; Panayiotidis P; Megalakaki A; Papaioannou M; Liapis K; Dryllis G; Tsokanas D; Kourakli A; Symeonidis A; Viniou NA; Kotsianidis I
    Hematol Oncol; 2020 Oct; 38(4):541-553. PubMed ID: 32495951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Female and preserved platelet count subgroups of myelodysplastic syndrome patients benefit from standard-dose azacitidine.
    Ogawa S; Sakamoto T; Matsuoka R; Ishitsuka K; Ogino Y; Sootome A; Makishima K; Yoshida C; Ito Y; Shimizu S; Suyama T; Shinagawa A; Ito T; Obara N; Kusakabe M; Sakata-Yanagimoto M; Miyazaki Y; Nannya Y; Chiba S
    Cancer Rep (Hoboken); 2024 Jan; 7(1):e1938. PubMed ID: 38014499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.